MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Venus Concept Cost of Revenue 2011-2026 | VERO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Venus Concept
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.5 M | 24.2 M | 33.5 M | 31.5 M | 26.6 M | 33.8 M | 23.3 M | 12.2 M | 10.4 M | 12.5 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.8 M | 10.4 M | 22.8 M |
Quarterly Cost of Revenue Venus Concept
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.96 M | 6.26 M | 4.89 M | - | 5.09 M | 4.73 M | 5.83 M | - | 5.43 M | 5.86 M | 6.83 M | - | 8.17 M | 8.22 M | 8.64 M | - | 7.26 M | 7.11 M | 7.36 M | - | 7.18 M | 5.1 M | 5.23 M | - | 7.39 M | 7.74 M | 6.52 M | - | 2.66 M | 2.51 M | 3.18 M | - | 2.47 M | 3.49 M | 3.09 M | - | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.64 M | 2.4 M | 5.56 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 3.72 | 0.95 % | $ 153 M |  USA |
 |
AxoGen
AXGN
|
57.9 M | $ 33.03 | -4.08 % | $ 1.52 B | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.07 | -1.09 % | $ 862 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.25 | 1.79 % | $ 1.66 B | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 36.66 | -0.27 % | $ 5.46 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 62.57 | -0.4 % | $ 92.6 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 9.41 | 0.48 % | $ 266 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 34.54 | -0.72 % | $ 1.07 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.62 | 5.64 % | $ 38.6 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.76 | 1.35 % | $ 350 M | USA |
 |
EDAP TMS S.A.
EDAP
|
36 M | $ 3.5 | 3.24 % | $ 131 M |  France |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 81.26 | 0.26 % | $ 47.5 B | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 170.52 | -0.05 % | $ 12.8 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.87 | 0.27 % | $ 1.14 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.31 | -2.31 % | $ 717 M | USA |
 |
Inogen
INGN
|
194 M | $ 6.42 | 3.38 % | $ 171 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 0.99 | 1.47 % | $ 16.8 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 96.6 | 0.38 % | $ 1.23 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 85.01 | -2.12 % | $ 2.95 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.95 | -0.68 % | $ 374 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.97 | -1.49 % | $ 71.4 M | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.38 | 3.38 % | $ 56.1 M | USA |
 |
Medtronic PLC
MDT
|
11.6 B | $ 86.52 | -0.13 % | $ 111 B | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 3.89 | -0.89 % | $ 575 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.69 | 3.22 % | $ 28.9 M | USA |